Boston Scientific Appoints New CMO of Interventional Cardiology

Natick, Mass.-based medical device company Boston Scientific Corporation has appointed Craig Thompson, M.D., as senior vice president and chief medical officer of the interventional cardiology business effective immediately. Thompson is hoped to play a key role in driving the development of medical solutions within the Boston Scientific Interventional Cardiology business.

Thompson previously served as director of invasive cardiology and vascular medicine at Yale New Haven Hospital (Connecticut), and associate professor of medicine at Yale University School of Medicine. He brings to Boston Scientific a wealth of clinical and academic experience, having performed thousands of structural cardiac, coronary and vascular catheter-based procedures.
Thompson also has served as an advisor for many cardiovascular device companies and he participated in the early development of technologies for the treatment of coronary total occlusions, including the BridgePoint coronary chronic total occlusion system acquired by Boston Scientific in 2012.

“As a pioneer in advanced coronary and vascular procedures and related device development, Craig’s expertise is a valuable asset,” said Kevin Ballinger, president of interventional cardiology at
Boston Scientific.

“Craig is a very experienced interventional cardiologist who is an important addition to our clinical team, increasing our ability to innovate medical solutions that provide unique value to physicians and patients,” added Keith Dawkins, M.D., executive vice president and global chief medical officer of the company.

Prior to Yale, Thompson served as director of cardiovascular catheterization and intervention at Dartmouth Hitchcock Medical Center/Dartmouth Medical School. He holds an undergraduate degree from the University of Southern Mississippi, medical degree from the University of Mississippi, and masters of medical science in clinical investigation from the Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology. Thompson completed post-doctoral training in clinical cardiology at Brigham and Women’s Hospital/Harvard Medical School and interventional cardiology and endovascular intervention at Massachusetts General Hospital/Harvard Medical School.

“Boston Scientific has a long-standing history pioneering interventional cardiology, with a commitment to meaningful innovation and a robust interventional cardiology portfolio,” said Thompson, “I’m delighted to work with the interventional cardiology team to further develop the technology pipeline and educational platforms to deliver solutions for patients with cardiovascular illness worldwide.”